Navigation Links
Chimerix Commences Phase 2 Clinical Study of CMX001 for Prevention of Adenovirus Disease in Pediatric and Adult Hematopoietic Stem Cell Transplant Patients
Date:7/13/2011

Durham, N.C., July 13, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).The company also announced that the U.S. Food and Drug Administration (FDA) has granted CMX001 Fast Track designation status for the development program for this indication.

The Phase 2 AdV HALT Trial is a randomized, placebo-controlled study intended to evaluate the safety and efficacy of preemptive treatment with CMX001 in order to prevent immunocompromised pediatric and adult patients with asymptomatic adenovirus infection from developing disease.  Adenoviruses area family of double-stranded DNA (dsDNA) viruses responsible for respiratory diseases, including pneumonia and bronchitis, as well as other infections including gastroenteritis and acute diarrheal diseases. In immunocompromised patients, including those who have undergone HSCT, adenovirus infections are recognized as a significant cause of morbidity and mortality.  Immunocompromised pediatric HSCT patients are particularly susceptible to serious and/or fatal adenovirus infections.

"Pediatric HSCT patients are at increased risk of life-threatening adenovirus infections–yet we have no approved treatment options," said Joanne Kurtzberg, MD, Director, Carolinas Cord Blood Bank Division Chief, Pediatric Blood and Marrow Transplantation, Duke University Medical Center, and a lead investigator of the study. "It is well known that this population is less tolerant of the toxicities associated with conventional antiviral drugs, especially the kidney toxicity associated with cidofovir, and we hope CM
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
2. Chimerix Joins International Network of Organizations to Cure Malaria
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
5. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
6. Chimerix Initiates Phase 1 Study of CMX157
7. Chimerix to Present at Upcoming Investor Conferences
8. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
9. Chimerixs PIM Conjugate Technology Reduces Risk of Nephrotoxicity for CMX001 and CMX157
10. Chimerix Presents Update on CMX001 Development to the World Health Organization Advisory Committee on Variola Virus Research
11. Chimerix Completes $45 Million Financing to Fund Further Development of Novel Antiviral Therapeutics CMX001 and CMX157
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Cempra, ... on developing differentiated antibiotics to meet critical medical ... announced that it presented data at the American ... Philadelphia demonstrating the antibacterial and ... Cempra,s prior Phase 2 clinical trial in outpatients ...
(Date:5/20/2013)... 20, 2013 Recognizing exciting and ... members to its 2013 Class of Young Professors. ... will provide this outstanding international group with more ... basic science to meet global challenges.     , The ... promising young and untenured research faculty working in ...
(Date:5/19/2013)... Switzerland’s MS Tûranor PlanetSolar , the ... record for a transatlantic crossing by a solar electric ... 25, 2013, the solar powered boat sailed 2,867miles (5,310 ... of 5.3 knots before reaching Marigot, St. Martin, in ... first-of-its-kind catamaran completed this year’s passage across the Atlantic ...
(Date:5/17/2013)... rejection occurs when the transplant recipient,s immune system identifies ... It was previously thought that T cells, the immune ... molecules known as chemokines in order to migrate to ... Journal of Clinical Investigation , Fadi Lakkis and colleagues ... that chemokine stimulation of T cells is not required ...
Breaking Biology Technology:Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 2DuPont Celebrates Scientific Innovation by Recognizing Young Professors 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6
... LEUVEN, Belgium, August 27 ThromboGenics NV,(Euronext Brussels: THR), a ... for eye disease, vascular disease,and cancer, is today issuing a ... period ending 30 June, 2009. , ... which,are key to its aim of becoming a profitable, integrated ...
... Massachusetts and CHEADLE, England, August 27 ,Cardea Technology, ... and configure their software tools for Vertebral Fracture,Assessment, ... on bone,densitometers, to exchange information and create reports ... Optasia Medical Ltd. has developed SpineAnalyzer(TM), a ...
... , , ATLANTA, Aug. 27 ... million extension of its Series C financing which was originally completed in ... $5 million in Series C preferred stock received warrants for an additional ... have up to 30 days from the delivery of Phase III top-line ...
Cached Biology Technology:ThromboGenics NV Announces Business Update and Half Year Results 2009 2ThromboGenics NV Announces Business Update and Half Year Results 2009 3ThromboGenics NV Announces Business Update and Half Year Results 2009 4ThromboGenics NV Announces Business Update and Half Year Results 2009 5ThromboGenics NV Announces Business Update and Half Year Results 2009 6ThromboGenics NV Announces Business Update and Half Year Results 2009 7ThromboGenics NV Announces Business Update and Half Year Results 2009 8ThromboGenics NV Announces Business Update and Half Year Results 2009 9ThromboGenics NV Announces Business Update and Half Year Results 2009 10ThromboGenics NV Announces Business Update and Half Year Results 2009 11ThromboGenics NV Announces Business Update and Half Year Results 2009 12ThromboGenics NV Announces Business Update and Half Year Results 2009 13ThromboGenics NV Announces Business Update and Half Year Results 2009 14ThromboGenics NV Announces Business Update and Half Year Results 2009 15Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools 2Alimera Sciences Closes $5 Million in Extended Series C Financing 2
(Date:5/18/2013)... presented at Digestive Disease Week (DDW) explores new ... lifestyle. , Individuals suffering from Crohn,s disease ... and poor quality of life. These symptoms can ... randomized, double blind, placebo-controlled study found for the ... significant relief of these symptoms. , "Our ...
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... The Federation of American Societies for Experimental Biology ... Institutes of Health (NIH) funding trends highlighting the devastating ... critical research. The FASEB analysis follows a May 15th ... MD, PhD, who testified that the $1.6 billion cut ... is "having a substantial impact on the scientific community." ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3First Atlanta Science Festival set for 2014 2
... A University of Leicester archaeologist has discovered a ... Staffordshire - believed to be the earliest archaeological evidence ... As reported in Post-Medieval Archaeology (volume 44/1) ... significance of the find is in the insights it ...
... your wedge may not help much, but mixing in longer ... studies have shown that variable practice improves the brain,s memory ... task. Cognitive neuroscientists at USC and UCLA describe the neural ... Nature Neuroscience . The researchers split 59 volunteers ...
... for regulating viruses that has worked its way into ... adult and fetal hemoglobin production, Medical College of Georgia ... to more targeted therapies for sickle cell patients whose ... throughout the body. Fetal hemoglobin, on the other ...
Cached Biology News:Archaeology find sheds new light on family pets 2Why (smart) practice makes perfect 2Modulator of fetal hemoglobin switch may target sickle cell disease 2Modulator of fetal hemoglobin switch may target sickle cell disease 3
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
p-Raf-1 (Ser 338/Tyr 341)-R...
Biology Products: